Found: 7
Select item for more details and to access through your institution.
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1754, doi. 10.1111/dom.14389
- By:
- Publication type:
- Article
Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1111, doi. 10.1111/dom.14314
- By:
- Publication type:
- Article
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase 3a clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 116, doi. 10.1111/dom.14198
- By:
- Publication type:
- Article
Type A insulin resistance syndrome misdiagnosed as polycystic ovary syndrome: a case report.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus.
- Published in:
- Experimental & Therapeutic Medicine, 2017, v. 14, n. 4, p. 3279, doi. 10.3892/etm.2017.4863
- By:
- Publication type:
- Article
ABCC8 -Related Maturity-Onset Diabetes of the Young (MODY12): A Report of a Chinese Family.
- Published in:
- Frontiers in Endocrinology, 2020, v. 11, p. N.PAG, doi. 10.3389/fendo.2020.00645
- By:
- Publication type:
- Article
Exenatide enhances INS-1 rat pancreatic β-cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.
- Published in:
- Molecular Medicine Reports, 2014, v. 10, n. 5, p. 2447, doi. 10.3892/mmr.2014.2538
- By:
- Publication type:
- Article